DE69925459D1 - Verfahren zur herstellung von hochreinen hmg-coa reductase inhibitoren - Google Patents

Verfahren zur herstellung von hochreinen hmg-coa reductase inhibitoren

Info

Publication number
DE69925459D1
DE69925459D1 DE69925459T DE69925459T DE69925459D1 DE 69925459 D1 DE69925459 D1 DE 69925459D1 DE 69925459 T DE69925459 T DE 69925459T DE 69925459 T DE69925459 T DE 69925459T DE 69925459 D1 DE69925459 D1 DE 69925459D1
Authority
DE
Germany
Prior art keywords
coa reductase
hmg
reductase inhibitor
crystallization
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69925459T
Other languages
English (en)
Other versions
DE69925459T2 (de
Inventor
Zlatko Pflaum
Dusan Milivojevic
David Senica
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lek Pharmaceuticals dd
Original Assignee
Lek Pharmaceuticals and Chemical Co dd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20432203&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69925459(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lek Pharmaceuticals and Chemical Co dd filed Critical Lek Pharmaceuticals and Chemical Co dd
Application granted granted Critical
Publication of DE69925459D1 publication Critical patent/DE69925459D1/de
Publication of DE69925459T2 publication Critical patent/DE69925459T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/42—Hydroxy-carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02—Oxygen as only ring hetero atoms
    • C12P17/06—Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/62—Carboxylic acid esters

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
DE69925459T 1998-02-18 1999-02-17 Verfahren zur herstellung von hochreinen hmg-coa reductase inhibitoren Expired - Lifetime DE69925459T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SI9800046A SI9800046A (sl) 1998-02-18 1998-02-18 Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze visoke čistosti
SI9800046 1998-02-18
PCT/IB1999/000808 WO1999042601A1 (en) 1998-02-18 1999-02-17 PROCESS FOR THE OBTAINING OF HMG-CoA REDUCTASE INHIBITORS OF HIGH PURITY

Publications (2)

Publication Number Publication Date
DE69925459D1 true DE69925459D1 (de) 2005-06-30
DE69925459T2 DE69925459T2 (de) 2006-04-27

Family

ID=20432203

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69925459T Expired - Lifetime DE69925459T2 (de) 1998-02-18 1999-02-17 Verfahren zur herstellung von hochreinen hmg-coa reductase inhibitoren

Country Status (21)

Country Link
US (1) US6825015B1 (de)
EP (1) EP1054993B1 (de)
JP (2) JP2002504345A (de)
KR (1) KR100582620B1 (de)
CN (1) CN1206363C (de)
AT (1) ATE296357T1 (de)
AU (1) AU743619B2 (de)
BG (1) BG64289B1 (de)
CA (1) CA2321052A1 (de)
CZ (1) CZ297093B6 (de)
DE (1) DE69925459T2 (de)
HR (1) HRP20000541A2 (de)
HU (1) HUP0100820A3 (de)
IL (1) IL137782A0 (de)
PL (1) PL193510B1 (de)
RO (1) RO120922B1 (de)
RU (1) RU2235130C2 (de)
SI (2) SI9800046A (de)
SK (1) SK285074B6 (de)
WO (1) WO1999042601A1 (de)
YU (1) YU50100A (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02005283A (es) * 1999-11-30 2003-10-06 Biogal Gyogyszergyar Proceso para recuperar compuestos estatina de un caldo de fermentacion.
KR20020062340A (ko) 1999-12-14 2002-07-25 비오갈 기오기스제르갸르 알티. 신규 형태의 프라바스타틴 나트륨
WO2001062949A1 (en) * 2000-02-24 2001-08-30 Biogal Gyogyszergyar Rt Method of purifying a fermentation broth
TR200403001T3 (tr) 2000-03-03 2005-02-21 Plus Chemical, S.A. Lovastatin ve simvastatinin, azaltılmış dimerik katışkı seviyelerine sahip olacak şekilde arıtılması için bir işlem
IN192861B (de) * 2000-06-30 2004-05-22 Ranbaxy Lab Ltd
US6936731B2 (en) * 2000-10-05 2005-08-30 TEVA Gyógyszergyár Részvénytársaság Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
US6716615B2 (en) 2002-02-27 2004-04-06 Yung Shin Pharmaceutical Ind. Co., Ltd. Strains of saccharaothrix, process for producing pravastatin using the strains and isolation process of (HMG)-CoA reductase
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
WO2005051372A2 (en) 2003-11-24 2005-06-09 Teva Gyógyszergyár Zártköruen Muködo Részvénytársaság Method of purifying pravastatin
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
ES2239533B1 (es) * 2004-03-01 2006-12-16 Ercros Industrial, S.A. Procedimiento para la obtencion de compactina.
CN102384955B (zh) * 2010-09-01 2014-04-30 北京北大维信生物科技有限公司 人体血浆中HMG－CoA还原酶抑制剂的定量分析方法
RU2585234C2 (ru) * 2013-12-27 2016-05-27 Открытое акционерное общество "Красфарма" Способ получения компактина
RU2585233C2 (ru) * 2013-12-27 2016-05-27 Открытое акционерное общество "Красфарма" Промышленный способ получения компактина

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4319039A (en) 1979-06-15 1982-03-09 Merck & Co., Inc. Preparation of ammonium salt of hypocholesteremic fermentation product
US4294846A (en) * 1979-09-21 1981-10-13 Merck & Co., Inc. Hypocholesteremic fermentation products and products of preparation
PT85109A (en) * 1986-06-23 1987-07-01 Merck & Co Inc Process for the preparation of hydroxy-tetrahydropyranone derivatives or corresponding ring opened dihydroxy acids which are hmg-coa reductase inhibitors
US4965200A (en) * 1989-06-23 1990-10-23 Merck & Co., Inc. Process for the preparation of 3-keto, 5-hydroxy simvastatin analogs
US5202029A (en) 1991-03-13 1993-04-13 Caron Kabushiki Kaisha Process for purification of hmg-coa reductase inhibitors
ATE189804T1 (de) * 1995-08-03 2000-03-15 Dsm Nv Selektives verfahren zur deacylierung von acylverbindungen
CA2243592C (en) * 1995-12-06 2001-12-25 Antibiotic Co. Method of production of lovastatin
HUP9902352A1 (hu) 1999-07-12 2000-09-28 Gyógyszerkutató Intézet Kft. Eljárás pravasztatin mikrobiológiai előállítására

Also Published As

Publication number Publication date
WO1999042601A1 (en) 1999-08-26
HRP20000541A2 (en) 2001-12-31
KR100582620B1 (ko) 2006-05-23
SI1054993T1 (en) 2005-10-31
PL193510B1 (pl) 2007-02-28
CA2321052A1 (en) 1999-08-26
JP2005110693A (ja) 2005-04-28
CN1291238A (zh) 2001-04-11
BG64289B1 (bg) 2004-08-31
SK285074B6 (sk) 2006-05-04
SI9800046A (sl) 1999-08-31
RO120922B1 (ro) 2006-09-29
ATE296357T1 (de) 2005-06-15
YU50100A (sh) 2003-07-07
PL342513A1 (en) 2001-06-18
SK11852000A3 (sk) 2001-05-10
IL137782A0 (en) 2001-10-31
CZ20002856A3 (cs) 2000-11-15
HUP0100820A3 (en) 2003-07-28
AU3438499A (en) 1999-09-06
DE69925459T2 (de) 2006-04-27
BG104696A (en) 2001-07-31
RU2235130C2 (ru) 2004-08-27
EP1054993B1 (de) 2005-05-25
KR20010041024A (ko) 2001-05-15
JP2002504345A (ja) 2002-02-12
US6825015B1 (en) 2004-11-30
EP1054993A1 (de) 2000-11-29
CZ297093B6 (cs) 2006-09-13
HUP0100820A2 (hu) 2001-08-28
AU743619B2 (en) 2002-01-31
CN1206363C (zh) 2005-06-15

Similar Documents

Publication Publication Date Title
DE69925459D1 (de) Verfahren zur herstellung von hochreinen hmg-coa reductase inhibitoren
ATE126829T1 (de) Verfahren zur herstellung von salzen des l- ornithins.
RU2000124064A (ru) Способ получения ингибиторов hmg-coa-редуктазы высокой степени чистоты
WO2001068893A3 (en) Soapstock hydrolysis and acidulation by acidogenic bacteria
BR0200489B1 (pt) composição contendo nitrogênio orgánico, e, fertilizante.
ATE240918T1 (de) Verfahren zur reduktion von carbonylverbindungen
ATE278800T1 (de) Verbessertes verfahren zur fermentativer herstellung von penizillin
EP0927755A3 (de) Haloacetoacetatreductase,Verfahren zur Herstellung und Verfahren zur Herstellung von Alcoholen damit
ID26888A (id) Proses produksi fermentasi cephalosporin
ATE232910T1 (de) Syntheseverfahren für inhibitoren der hmg-coa- reduktase
DE69828940D1 (de) Verbessertes verfahren zur fermentativen herstellung von cephalosporin
DK0867515T3 (da) Fremgangsmåde til isolering af et farmaceutisk acceptabelt alkalimetalsalt af clavulansyre
SE0003958D0 (sv) Method for growth of microorganisms
NO20045513L (no) Fremgangmate for fremstiling av konjugert linolsyre
DE59304635D1 (de) Verfahren zur fermentativen herstellung von 2-hydroxyphenylessigsäure
US5258290A (en) Fermentation process for the production of β-carboline derivatives by Myrothecium verrucaria
KR890003955A (ko) 광학 활성 인-함유 작용성 아세트산 유도체의 효소적 제조방밥
WO2002022849A3 (en) Enzymatic resolution of aryl- and thio-substituted acids
WO2000052012A3 (en) A method for synthesizing porphyrin compounds
RU2001132333A (ru) Способ получения производных стероидных гликозидов RUSCUS ACULEATUS
KR930021796A (ko) 미생물에 의한 말로닐-7-아미노세팔로스포린산 유도체의 제조방법
NO20013435D0 (no) Fremgangsmåte for fremstilling av bisykliske forbindelser og anvendelse av fremgangsmåten til fremstilling av en ICE-inhibitorforbindelse
KR930013137A (ko) 리보플라빈의 제조방법
EP0795607A3 (de) Verfahren zur Herstellung einer Lakton
DE69222068D1 (de) Verfahren zur herstellung von aromaestern durch eine enzymatisch katalysierte reaktion

Legal Events

Date Code Title Description
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN